邻氨基-N,N-二甲基苯甲酰胺 | 6526-66-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 邻氨基-N,N-二甲基苯甲酰胺
• 中文别名: 2-氨基-N,N-二甲基苯甲酰胺
• 英文名称: 2-amino-N,N-dimethylbenzamide
• CAS: 6526-66-5
• 化学式: C₉H₁₂N₂O
• mdl: MFCD01168906
• 分子量: 164.207
• InChiKey: DPXIIVXPZPOINE-UHFFFAOYSA-N

物化性质

• 熔点：
  88 °C(Solv: methanol (67-56-1); water (7732-18-5))
• 沸点：
  332.3±25.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  邻氨基-N,N-二甲基苯甲酰胺 在 tetrafluoroboric acid 、 四硫富瓦烯 、 sodium nitrite 作用下， 以 水 、 丙酮 为溶剂， 反应 0.5h， 生成 N-甲基苯甲酰胺
  参考文献：
  名称：

  Murphy, John A.; Roome, Stephen J., Journal of the Chemical Society. Perkin transactions I, 1995, # 11, p. 1349 - 1358

  摘要：

  DOI：
• 作为产物：
  描述：

  邻氨基苯甲酸 在 氯化亚砜 作用下， 以 乙醚 为溶剂， 反应 5.0h， 生成 邻氨基-N,N-二甲基苯甲酰胺
  参考文献：
  名称：

  Synthesis, antimicrobial evaluation, ot-QSAR and mt-QSAR studies of 2-amino benzoic acid derivatives

  摘要：

  A series of 2-amino benzoic acid derivatives (1-28) were synthesized and evaluated for their in vitro antimicrobial activity against the panel of Gram positive, Gram negative bacterial and fungal strains. The results of antimicrobial studies indicated that, in general, the synthesized compounds were found to be bacteriostatic and fungistatic in action. QSAR studies performed by the development of one target and multi target models indicated that multi-target model was effective in describing the antimicrobial activity as well demonstrated the effect of structural parameters viz. LUMO, (3)chi(v) and W on antimicrobial activity of 2-amino benzoic acid derivatives.

  DOI：

  10.1007/s00044-010-9537-5

文献信息

• [EN] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS<br/>[FR] 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES ET 4-PYRAZOLYL-N-HÉTÉROARYLPYRIMIDIN-2-AMINES EN TANT QU'INHIBITEURS DE JANUS KINASE
  申请人：INCYTE CORP

  公开号：WO2009064835A1

  公开（公告）日：2009-05-22

  The present invention provides substituted bicyclic heteroaryl compounds, 5 including, for example, 4-pyrazoIyI-N-arylpyrirnidin-2-arnines and 4-pyrazolyl-N-heteroarylpyτimidin-2-amines that modulate the activity of kinases and are useful in the treatment of diseases related to activity of kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.formule :(1)

  本发明提供了取代的双环杂环芳基化合物，包括例如4-吡唑基-N-芳基吡啶-2-胺和4-吡唑基-N-杂环芳基嘧啶-2-胺，这些化合物调节激酶的活性，在治疗与激酶活性相关的疾病方面具有用处，例如免疫相关疾病、皮肤疾病、髓细胞增生性疾病、癌症和其他疾病。公式：(1)
• Potent, Selective, and Cell Active Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor Developed by Structure-Based Virtual Screening and Hit Optimization
  作者：Ruifeng Mao、Jingwei Shao、Kongkai Zhu、Yuanyuan Zhang、Hong Ding、Chenhua Zhang、Zhe Shi、Hualiang Jiang、Dequn Sun、Wenhu Duan、Cheng Luo

  DOI：10.1021/acs.jmedchem.7b00587

  日期：2017.7.27

  been validated as an anticancer target in mantle cell lymphoma. In this study, we found a potent and selective PRMT5 inhibitor by performing structure-based virtual screening and hit optimization. The identified compound 17 (IC50 = 0.33 μM) exhibited a broad selectivity against a panel of other methyltransferases. The direct binding of 17 to PRMT5 was validated by surface plasmon resonance experiments

  PRMT5在多种细胞过程中起着重要作用，并在几种人类恶性肿瘤中被上调。此外，PRMT5已被确认为套细胞淋巴瘤的抗癌靶标。在这项研究中，我们通过执行基于结构的虚拟筛选和命中优化，发现了一种有效的选择性PRMT5抑制剂。鉴定出的化合物17（IC 50 = 0.33μM）对一组其他甲基转移酶表现出广泛的选择性。通过表面等离振子共振实验验证了17与PRMT5的直接结合，K d为0.987μM。动力学实验表明17是除底物以外的SAM竞争性抑制剂。另外17提示对MV4-11细胞具有选择性的抗增殖作用，进一步的研究表明，细胞抗肿瘤活性的机制是由于PRMT5介导的SmD3甲基化的抑制。17可能是一种有前途的先导化合物，可以进一步了解PRMT5，并可能有助于开发白血病适应症的治疗方法。
• ANTHRANILAMIDE INHIBITORS OF AURORA KINASE
  申请人：Johnson Neil W.

  公开号：US20080182852A1

  公开（公告）日：2008-07-31

  The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof; where R 1 , R 2 , R 3 , R 4 , r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.

  本发明涉及以下公式所代表的化合物： 或其药学上可接受的盐； 其中R1、R2、R3、R4、r和s如前所定义。本发明的化合物在治疗与Aurora激酶活性相关的疾病，如癌症方面是有用的。
• \x9b3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine,
  申请人：Syntex (U.S.A.) Inc.

  公开号：US05688795A1

  公开（公告）日：1997-11-18

  The present invention relates to novel .alpha..sub.1 -adrenoceptor antagonists of Formula I: ##STR1## in which: p is 0 or 1; t is 0, 1 or 2; X is O, S or NR.sup.6 (in which R.sup.6 is hydro or (C.sub.1-6)alkyl); Y and Z are independently CH or N; R.sup.1 is hydro, hydroxy, halo, nitro, amino, cyano, (C.sub.1-4)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl (C.sub.1-4)alkyl, heteroaryl (C.sub.1-4)alkyl, (C.sub.1-6)alkyloxy, (C.sub.3-6)cycloalkyloxy, (C.sub.3-6)cycloalkyl (C.sub.1-4)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl (C.sub.1-4)alkyloxy or heteroaryl (C.sub.1-4)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano); R.sup.2 is hydro, hydroxy, halo, cyano, (C.sub.1-6)alkyl or (C.sub.1-6)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms); R.sup.3 is -C (O)R.sup.7 (wherein R.sup.7 is (C.sub.1-6)alkyl, (C.sub.3-6)cycloalkyl, di(C.sub.1-4)alkylamino, N-(C.sub.1-4)alkyl-N-(C.sub.1-4)alkyloxyamino, (C.sub.1-4)alkyl((C.sub.1-4)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl); R.sup.4 is halo, hydroxy, cyano, (C.sub.1-6)alkyl or (C.sub.1-6)alkyloxy; and R.sup.5 is (C.sub.1-6)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof.

  本发明涉及以下式I的新型α1-肾上腺素受体拮抗剂：##STR1## 其中：p为0或1；t为0, 1或2；X为O、S或NR.sup.6（其中R.sup.6为羟基或（C.sub.1-6）烷基）；Y和Z独立地为CH或N；R.sup.1为羟基、羟基、卤素、硝基、氨基、氰基、（C.sub.1-4）烷基硫基、乙酰氨基、三氟乙酰氨基、甲磺酰氨基、（C.sub.1-6）烷基、（C.sub.3-6）环烷基、（C.sub.3-6）环烷基（C.sub.1-4）烷基、噁唑-2-基、芳基、杂环芳基、芳基（C.sub.1-4）烷基、杂环芳基（C.sub.1-4）烷基、（C.sub.1-6）烷氧基、（C.sub.3-6）环烷氧基、（C.sub.3-6）环烷基（C.sub.1-4）烷氧基、2-丙炔氧基、芳氧基、杂环芳氧基、芳基（C.sub.1-4）烷氧基或杂环芳基（C.sub.1-4）烷氧基（其中烷基可选择性地用1至3个卤原子取代，芳基或杂环芳基可选择性地用1至2个独立选择的卤素和氰基取代）；R.sup.2为羟基、羟基、卤素、氰基、（C.sub.1-6）烷基或（C.sub.1-6）烷氧基（其中烷基可选择性地用1至3个卤原子取代）；R.sup.3为-C（O）R.sup.7（其中R.sup.7为（C.sub.1-6）烷基、（C.sub.3-6）环烷基、二（C.sub.1-4）烷基氨基、N-（C.sub.1-4）烷基-N-（C.sub.1-4）烷氧基氨基、（C.sub.1-4）烷基（（C.sub.1-4）烷氧基）氨基、吡咯烷-1-基、哌啶-1-基、吗啉-4-基或哌嗪-1-基）；R.sup.4为卤素、羟基、氰基、（C.sub.1-6）烷基或（C.sub.1-6）烷氧基；R.sup.5为（C.sub.1-6）烷基；以及其药学上可接受的盐和N-氧化物。
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20170015655A1

  公开（公告）日：2017-01-19

  The present invention provide a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of autoimmune diseases and/or inflammatory diseases, graft versus host disease, cancers, central nervous diseases including neurodegenerative diseases, Charcot-Marie-Tooth disease and the like, and a pharmaceutical composition comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供一种具有HDAC抑制作用的杂环化合物，用于治疗自身免疫疾病和/或炎症性疾病、移植物抗宿主病、癌症、包括神经退行性疾病、沙科-玛丽-图特病等在内的中枢神经疾病，以及包含该化合物的药物组合物。本发明涉及一种由下式（I）表示的化合物： 其中每个符号如规范中定义，或其盐。